The global congenital hyperinsulinism market size was valued at USD 153.25 million in 2022 and is projected to grow at a CAGR of 4.80% during the forecast period of 2023-2031 to reach a value of USD 233.60 million by 2031. The market growth can be attributed to the rising awareness about the condition and advances in diagnostic and treatment options.
There are various genetic mutations associated with congenital hyperinsulinism, which can be inherited in an autosomal recessive or autosomal dominant manner. Mutations in genes such as ABCC8, KCNJ11, GLUD1, GCK, HADH, SLC16A1, UCP2, and HNF4A have been identified in individuals with congenital hyperinsulinism. These genetic mutations impact the function of pancreatic beta cells, leading to the excessive secretion of insulin and subsequent hypoglycaemia.
North America currently dominates the global congenital hyperinsulinism market, accounting for a significant share of the global market. The region's large market share is driven by factors such as a higher prevalence of congenital hyperinsulinism, a well-established healthcare infrastructure, and strong investment in research and development. In addition, the growing adoption of advanced diagnostic techniques and novel therapeutic approaches is further driving the growth of the market in North America.
Europe is also a significant market for congenital hyperinsulinism, with countries such as the United Kingdom, Germany, and France leading the way. The region's market growth is driven by factors such as a large population base, increasing awareness of congenital hyperinsulinism, and government initiatives to address rare diseases. Additionally, the region has a well-established healthcare system, which supports the delivery of diagnostic and treatment services.
Asia Pacific is another region that is experiencing significant growth in the congenital hyperinsulinism market. The region's market growth is driven by factors such as a large population base, increasing awareness of congenital hyperinsulinism, and the growing adoption of advanced diagnostic and treatment technologies. In addition, government initiatives to address rare diseases are helping to drive the growth of the market in the region.
Global Congenital Hyperinsulinism Market: Introduction
Congenital hyperinsulinism is a rare genetic disorder characterized by excessive insulin secretion, leading to hypoglycaemia. The condition primarily affects infants and can cause seizures, developmental delays, and other severe complications if left untreated. The increasing prevalence of congenital hyperinsulinism, along with growing awareness about the condition, is driving the demand for effective diagnostic and treatment options. Technological advancements in genetic testing and imaging techniques, coupled with the development of novel therapeutic approaches, are expected to drive market growth.Congenital Hyperinsulinism Epidemiology
The exact prevalence of congenital hyperinsulinism is unknown, but the prevalence of congenital hyperinsulinism is estimated to affect approximately 1 in 25,000 to 50,000 live births worldwide. However, this figure may vary across different populations and regions due to differences in genetic factors, demographics, and diagnostic practices. Some specific populations, such as those with consanguineous marriages or certain ethnic groups, may have a higher prevalence of congenital hyperinsulinism.There are various genetic mutations associated with congenital hyperinsulinism, which can be inherited in an autosomal recessive or autosomal dominant manner. Mutations in genes such as ABCC8, KCNJ11, GLUD1, GCK, HADH, SLC16A1, UCP2, and HNF4A have been identified in individuals with congenital hyperinsulinism. These genetic mutations impact the function of pancreatic beta cells, leading to the excessive secretion of insulin and subsequent hypoglycaemia.
Congenital Hyperinsulinism Market Segmentations
The market can be segmented based on diagnosis method, treatment methods, treatment channel, and region:Market Breakup by Diagnosis Methods
- Genetic Testing
- Blood Tests
- Others
Market Breakup by Treatment Methods
Medication
- Diazoxide
- Octreotide
- Glucagon
- Insulin
- Others
- Surgical Treatment
- Others
Market Breakup by Treatment Channel
- Private
- Publics
Market Breakup by Region
North America
- United States of America
- Canada
Europe
- United Kingdom
- Germany
- France
- Italy
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Congenital Hyperinsulinism Market Analysis
The global congenital hyperinsulinism market has experienced significant growth over the past few years, driven by factors such as the increasing prevalence of congenital hyperinsulinism, rising awareness about the condition, and advances in diagnostic and treatment options. One key driver of growth in the congenital hyperinsulinism market is the increasing prevalence of the condition.North America currently dominates the global congenital hyperinsulinism market, accounting for a significant share of the global market. The region's large market share is driven by factors such as a higher prevalence of congenital hyperinsulinism, a well-established healthcare infrastructure, and strong investment in research and development. In addition, the growing adoption of advanced diagnostic techniques and novel therapeutic approaches is further driving the growth of the market in North America.
Europe is also a significant market for congenital hyperinsulinism, with countries such as the United Kingdom, Germany, and France leading the way. The region's market growth is driven by factors such as a large population base, increasing awareness of congenital hyperinsulinism, and government initiatives to address rare diseases. Additionally, the region has a well-established healthcare system, which supports the delivery of diagnostic and treatment services.
Asia Pacific is another region that is experiencing significant growth in the congenital hyperinsulinism market. The region's market growth is driven by factors such as a large population base, increasing awareness of congenital hyperinsulinism, and the growing adoption of advanced diagnostic and treatment technologies. In addition, government initiatives to address rare diseases are helping to drive the growth of the market in the region.
Key Players in the Global Congenital Hyperinsulinism Market
The report provides a detailed analysis of the key players involved in the congenital hyperinsulinism market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:- Eli Lilly
- Novo Nordisk
- Novartis AG
- Rezolute, Inc
- Eiger BioPharmaceuticals
- Zealand Pharma A/S
- Hanmi Pharmaceutical Co., Ltd
- Crinetics Pharmaceuticals, Inc
- AmideBio LLC
Table of Contents
1 Preface
4 Congenital Hyperinsulinism Overview
5 Patient Profile
6 Current Scenario Evaluation
7 Challenges and Unmet Needs
8 Global Congenital Hyperinsulinism Treatment Market
9 North America Congenital Hyperinsulinism Treatment Market
10 Europe Congenital Hyperinsulinism Treatment Market
11 Asia Pacific Congenital Hyperinsulinism Treatment Market
12 Latin America Congenital Hyperinsulinism Treatment Market
13 Middle East and Africa Congenital Hyperinsulinism Treatment Market
14 Congenital Hyperinsulinism Treatment Market Dynamics
15 Supplier Landscape
16 Global Congenital Hyperinsulinism Treatment Market- Distribution Model (Additional Insight)
17 Payment Methods (Additional Insight)
Companies Mentioned
- Eli Lilly
- Novo Nordisk
- Novartis AG
- Rezolute, Inc.
- Eiger BioPharmaceuticals.
- Zealand Pharma A/S
- Hanmi Pharmaceutical Co., Ltd.
- Crinetics Pharmaceuticals, Inc.
- AmideBio LLC
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 147 |
| Published | March 2023 |
| Forecast Period | 2023 - 2031 |
| Estimated Market Value ( USD | $ 160.6 Million |
| Forecasted Market Value ( USD | $ 233.6 Million |
| Compound Annual Growth Rate | 4.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
Related Reports
Congenital Hyperinsulinism (CHI) - Pipeline Insight, 2024
- Clinical Trials
- 60 Pages
- Global
From
From
Polycystic ovary syndrome - Pipeline Insight, 2024
- Drug Pipelines
- 60 Pages
- Global
From
From
About the Congenital Hyperinsulinism Drug Market
Congenital Hyperinsulinism (CHI) is a rare endocrine disorder caused by an overproduction of insulin. It is characterized by persistent hypoglycemia, which can lead to seizures, coma, and even death if left untreated. Treatment for CHI typically involves the use of drugs to reduce the amount of insulin produced by the body. These drugs are known as Congenital Hyperinsulinism Drugs (CHID). CHID are typically used in combination with dietary and lifestyle modifications to reduce the risk of Read more
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF. 
